Hantz Financial Services’s Viking Therapeutics VKTX Stock Holding History

Hantz Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1K	Buy	26 +25	+2,500%	+$804	﹤0.01%	2406
2025 Q4	$0	Hold	1	–	–	﹤0.01%	2546
2025 Q3	$0	Hold	1	–	–	﹤0.01%	2458
2025 Q2	$0	Sell	1 -68	-99%	-$1.79K	﹤0.01%	2309
2025 Q1	$2K	Buy	+69	New	+$2.18K	﹤0.01%	1436
2023 Q4	–	Sell	-40	Closed	–	–	1230
2023 Q3	$0	Hold	40	–	–	﹤0.01%	1190
2023 Q2	$1K	Hold	40	–	–	﹤0.01%	1061
2023 Q1	$1K	Buy	+40	New	+$413	﹤0.01%	1082

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hantz Financial Services's VKTX Position: Q1 2026 in Review

Hantz Financial Services increased its Viking Therapeutics (VKTX) stake by 2,500% in Q1 2026, buying an estimated $804 and bringing the position to 26 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

Hantz Financial Services first reported a position in VKTX in Q1 2023 and has held it in 8 quarters since. The position peaked at $2K in Q1 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Hantz Financial Services held 26 shares of Viking Therapeutics worth $1K as of Q1 2026.
Hantz Financial Services bought 25 Viking Therapeutics shares in Q1 2026, an estimated $804.
Viking Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2406 holding.
Hantz Financial Services first reported a position in Viking Therapeutics in Q1 2023 and has held it in 8 quarters since.
Hantz Financial Services's Viking Therapeutics position peaked at $2K in Q1 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.